/
ASMB
$26.96+$0.22 (+0.82%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$529.9M
20M shares
52-week range
$16.90 – $39.71
44% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.71%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-19.60
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.8M | $16.0M | $79.1M | $6.3M | $0 | $7.2M | $28.5M | $72.3M |
| Cost of revenue | $72.7M | $85.3M | $101.3M | $0 | $69.1M | $48.9M | $55.9M | $129.0K |
| Gross profit | −$57.9M | −$69.4M | −$22.2M | $6.3M | −$69.1M | −$41.7M | −$27.4M | $72.2M |
| Gross margin | -391.4% | -434.5% | -28.1% | 100.0% | — | -582.7% | -96.1% | 99.8% |
| R&D | $72.7M | $85.8M | $106.8M | $68.5M | $70.0M | $48.9M | $55.9M | $64.8M |
| Operating income | −$92.7M | −$102.7M | −$64.8M | −$132.7M | −$94.1M | −$64.6M | −$45.4M | −$12.1M |
| EBITDA | −$92.7M | −$103.7M | −$58.4M | −$90.6M | −$92.5M | −$60.7M | −$39.7M | −$6.0M |
| Net income | −$90.8M | −$97.6M | −$62.2M | −$129.9M | −$93.1M | −$61.2M | −$40.2M | −$6.1M |
| Net margin | -613.0% | -611.6% | -78.6% | -2076.4% | — | -854.8% | -140.9% | -8.5% |
| EPS (diluted) | -39.80 | -27.80 | -15.00 | -36.00 | -22.82 | -13.38 | -6.69 | -0.55 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $45M | $-1.70 | $-3.13–$-0.61 | 2 |
| 2027 | $43M | $-3.21 | $-5.91–$-1.16 | 2 |
| 2028 | $66M | $-2.50 | $-5.37–$0.38 | 2 |
| 2029 | $28M | $-3.78 | $-6.96–$-1.36 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Assembly Biosciences, Inc
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
www.assemblybio.com- Employees
- 73
- IPO / List date
- Dec 17, 2010
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds ASMB.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 15,651 | $434.3K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-02-12 | 1-for-12reverse |
Recent trades on TradeandTell
No one on the platform has traded ASMB yet.
